These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15227626)

  • 1. Highly active antiretroviral therapy and viral response in HIV type 2 infection.
    Mullins C; Eisen G; Popper S; Dieng Sarr A; Sankale JL; Berger JJ; Wright SB; Chang HR; Coste G; Cooley TP; Rice P; Skolnik PR; Sullivan M; Kanki PJ
    Clin Infect Dis; 2004 Jun; 38(12):1771-9. PubMed ID: 15227626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
    Mwamburi DM; Wilson IB; Jacobson DL; Spiegelman D; Gorbach SL; Knox TA; Wanke CA
    Clin Infect Dis; 2005 Jan; 40(1):167-73. PubMed ID: 15614708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of highly active antiretroviral therapy (HAART) in a cohort of patients with HIV infection in Mexico].
    Jáuregui Camargo L; Ruiz-Palacios G; Guerrero Almeida L; Niño Oberto S; Peasey A; Sierra Madero J
    Rev Invest Clin; 2003; 55(1):10-7. PubMed ID: 12708158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implant-prosthetic treatment in HIV-infected patients receiving highly active antiretroviral therapy: report of cases.
    Strietzel FP; Rothe S; Reichart PA; Schmidt-Westhausen AM
    Int J Oral Maxillofac Implants; 2006; 21(6):951-6. PubMed ID: 17190306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.